These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31419433)

  • 61. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [No Abstract]   [Full Text] [Related]  

  • 62. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
    Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination of Multiparametric Magnetic Resonance Imaging With Elastic-fusion Biopsy Has a High Sensitivity in Detecting Clinically Significant Prostate Cancer in Daily Practice.
    Cecchini S; Castellani D; Fabbietti P; Mazzucchelli R; Montironi R; Cecarini M; Carnevali F; Pierangeli T; Dellabella M; Ravasi E
    Clin Genitourin Cancer; 2020 Oct; 18(5):e501-e509. PubMed ID: 32147365
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reporting and Data System Category ≥3.
    Shoji S; Kaya T; Tanaka Y; Uemura K; Kusaka T; Takahashi K; Yuzuriha S; Kano T; Hanada I; Umemoto T; Ogawa T; Nakano M; Kawakami M; Nitta M; Hasegawa M; Hashida K; Hasebe T; Kaneko T; Okada J; Asai S; Miyajima A
    J Urol; 2023 Jan; 209(1):187-197. PubMed ID: 36067387
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness of Bi-Parametric MR/US Fusion Biopsy for Detecting Clinically Significant Prostate Cancer in Prostate Biopsy Naïve Men.
    Kim YJ; Huh JS; Park KK
    Yonsei Med J; 2019 Apr; 60(4):346-351. PubMed ID: 30900420
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MRI-Targeted, Systematic, or Combined Biopsy for Detecting Clinically Significant Prostate Cancer.
    Burk KS; Naik S; Lacson R; Tuncali K; Lee LK; Tempany C; Cole AP; Trinh QD; Kibel AS; Khorasani R
    J Am Coll Radiol; 2023 Jul; 20(7):687-695. PubMed ID: 37315913
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systematic Biopsy Does Not Contribute to Disease Upgrading in Patients Undergoing Targeted Biopsy for PI-RADS 5 Lesions Identified on Magnetic Resonance Imaging in the Course of Active Surveillance for Prostate Cancer.
    Arabi A; Deebajah M; Yaguchi G; Pantelic M; Williamson S; Gupta N; Park H; Peabody J; Menon M; Dabaja A; Alanee S
    Urology; 2019 Dec; 134():168-172. PubMed ID: 31479660
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Histopathological Analysis of False-positive Lesions in mpMRI/TRUS Fusion Prostate Biopsy.
    Yamanaka R; Sekino Y; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Hayashi T; Teishima J; Takeshima Y; Honda Y; Awai K; Hinata N
    In Vivo; 2022; 36(1):496-500. PubMed ID: 34972754
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Should Targeted Biopsy be Performed in Patients Who Have Only Pi-rads 3 Lesions?
    Koparal MY; Sözen TS; Karşiyakali N; Akdoğan B; Özen H; Aslan G; Türkeri L
    Arch Esp Urol; 2022 Jun; 75(5):410-415. PubMed ID: 35983811
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 76. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
    Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
    BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer.
    Patel NU; Lind KE; Garg K; Crawford D; Werahera PN; Pokharel SS
    Abdom Radiol (NY); 2019 Feb; 44(2):705-712. PubMed ID: 30171296
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    Davenport MS; Montgomery JS; Kunju LP; Siddiqui J; Shankar PR; Rajendiran T; Shao X; Lee E; Denton B; Barnett C; Piert M
    J Nucl Med; 2020 Mar; 61(3):337-343. PubMed ID: 31420496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.